Please login to the form below

Not currently logged in
Email:
Password:

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

JanssenJanssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone acetate), receiving the go-ahead to add an earlier stage of metastatic prostate cancer to the drug’s label.

Initially the once daily oral drug was approved in combination with predinson/prednisolone for the treatment of metastatic castration-resistance prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT and in patients where chemotherapy is not yet clinically indicated.

It was also originally approved for the same indication but in patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

However, the European Commission’s decision has extended Zytiga’s indication to include the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

Dr Ivo Winiger-Candolfi, oncology solid tumour therapy area lead, Janssen EMEA, said: “This EC approval is a major step forward for men living with prostate cancer across Europe and offers patients with newly-diagnosed high-risk mHSPC a new treatment option.”

Prostate cancer is the most common form of cancer in men throughout Europe and according to the Johnson and Johnson pharma group, patients with mHSPC, particularly with high-risk characteristics, have a poor prognosis.

Dr Winiger-Candolfi added: “We are encouraged by the data we have seen to date and remain committed to transforming outcomes for prostate cancer patients.

The approval from the EU regulators follows a recommendation from the Committee for Medical Products for Human Use (CHMP), which was based on the positive results of Janssen’s LATITUDE study.

Article by
Gemma Jones

23rd November 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics